83 results about "Kallikrein" patented technology

The invention belongs to the technical field of daily chemistry, and provides a triple compound acid composition with skin brightening and acne removing effects, a product and application of the triple compound acid composition and the product, the triple compound acid composition comprises mandelic acid, salicylic acid and succinic acid, and the mass ratio of the mandelic acid to the salicylic acid to the succinic acid is (3-6): (1-2): (1-2). The invention further provides a product containing the composition and application of the product. The composition provided by the invention is synergistically used, has a synergistic effect in the aspect of exfoliating, especially in the aspect of improving the activity of kallikrein 5 (KLK5), not only has the effects of biological skin glowing and exfoliating, but also can efficiently down-regulate the expression of I-type 5alpha-reductase genes, so that the synthesis of sebum is inhibited, and an oil control effect is achieved; in addition, the composition provided by the invention has the effects of brightening, inhibiting bacteria and resisting inflammation, has low sensitization, can be used for removing acnes, takes effect quickly and does not relapse.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention discloses a polypeptide composition for promoting skin desquamation and a preparation method and application thereof, the polypeptide composition comprises polypeptides and a polyol preservative, the polypeptides comprise a first polypeptide, a second polypeptide and a third polypeptide, and the first polypeptide is acetyl tetrapeptide-2; the second polypeptide comprises one or more of hyaluronic acid polypeptide, red scorpion toxin and palmitoyl tripeptide-5; and the third polypeptide is prepared from one or more of acetyl octapeptide-3, palmitoyl dipeptide-7, acetyl tetrapeptide-9 and acetyl tetrapeptide-11. The polypeptide composition can significantly up-regulate the gene expression of kallikrein through a synergistic effect and promote old cutin exfoliation; meanwhile, gene expression of metalloproteinase is inhibited, and light aging is delayed. The polypeptide composition disclosed by the invention can be prepared into various cosmetics and has multiple effects of promoting skin desquamation, resisting wrinkles and repairing barriers.

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more compounds of Formula I compounds, and methods for using the compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

The present invention provides compounds of Formula (I):or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and / or inflammatory disorders using the same.

The present invention provides compositions and methods for inhibiting thrombosis in subjects at risk of thrombosis, such as those with a genetic, acquired, or environmental risk of thrombosis. [Solution] The present invention provides RNAi agents, such as double-stranded RNAi agents, that target kallikrein B, plasma (Fletcher factor) 1 (KLKB1) gene, factor XII (Hageman factor (F12) gene, or kininogen 1 (KNG1) gene, as well as methods for inhibiting the expression of the KLKB1 gene, F12 gene, and / or KNG1 gene using such RNAi agents, and methods for treating subjects with hereditary angioedema (HAE) and / or contact activation pathway-related disorders.

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg9-Bradykinin and des-Arg10-Kallidin-like peptide.

The application belongs to the technical field of cosmetics and skin external preparation, and discloses a retinoid, a preparation method and application thereof. The compound is formed by covalently coupling a Schiff base or a kinin releasing enzyme cleavable peptide bond (L) and a free L-amino acid, a di- to hexapeptide or a C6-C22 fatty acid ester (P) of the retinol parent (R), and the structural general formula is R-L-P. The compound has a 12-week stability rate of ≥80% in a 25℃ aqueous preparation, is recognized by a keratin layer carboxylic acid esterase and a kinin releasing enzyme KLK-5 / KLK-7 after being applied to the skin, is subjected to enzymatic cutting in a skin acidic cuticle (pH 4.5-5.5) microenvironment, and releases free retinol at a fixed point. Compared with retinol palmitate, the in-situ release efficiency of the compound of the application is increased by 2.5-4.5 times, while the risk of systemic absorption is significantly reduced, and the incidence of sensitive skin irritation is ≤6.7%.

Aspects of the application provide dual inhibitor anti-KLK5 / KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and methods of using such proteins are described.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The present application relates to the preparation of new physiological and pharmaceutically active molecules, and belongs to the field of pharmaceutical synthesis chemistry, and relates to the design and preparation of a class of molecules capable of inhibiting the activity of human kallikrein. Firstly, fluoroacrylic acid and alcohol compounds are used as raw materials to obtain a class of fluoroallyl alcohol compounds; then the fluoroallyl alcohol is condensed with carboxylic acid compounds to obtain fluoroallyl carboxylic acid ester compounds with general formula (I) capable of inhibiting the activity of human kallikrein. The compounds are considered to be useful for treating diabetic complications, eye diseases and edema-related diseases. In addition, they have potential applications in the diagnosis and treatment of some cancers.

The present disclosure provides antibodies and polypeptides that specifically bind to kallikrein related peptidase 6 (KLK6). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Aspects of this application provide anti-KLK5 antibodies, anti-KLK7 antibodies, and anti-KLK5 / KLK7 antibodies (e.g., bispecific antibodies), as well as methods of using them to promote barrier function, reduce inflammation, and treat conditions such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis. Certain aspects of this disclosure relate to the recognition that a loss of balance between endogenous KLK proteases and associated protease inhibitors can lead to barrier dysfunction and induce inflammation (see, for example, Figure 1), which can result in inflammatory conditions, such as Netherton syndrome, eosinophilic esophagitis, and atopic dermatitis.

The present disclosure provides chimeric antigen receptors (CARs) that specifically target human kallikrein 2 (hK2), and immune responsive cells comprising such CARs, for use in the treatment of cancer.

The invention describes methods for administering anti-plasma kallikrein antibodies, e.g., dosing regimens, to treat plasma kallikrein associated disorders, including hereditary angioedema (HAE).

The present invention belongs to the field of biomedical technology and specifically relates to an anticoagulant polypeptide and its use in the preparation of a plasma kallikrein activity inhibitor. The anticoagulant polypeptide of the present invention comprises the amino acid sequence shown in SEQ ID No. 2. The anticoagulant polypeptide of the present invention can significantly inhibit plasma recalcification time and activated partial thromboplastin time, exhibits excellent anti-inflammatory thrombotic and stroke drug activity, has low bleeding risk and cytotoxicity, and is highly safe.

Provided is a non-human animal that is useful for analysis of a kallikrein-kinin system. A non-human animal that lacks the Kng1 gene and the Kng2 gene.

The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.

The application belongs to the technical field of daily chemicals, and provides a triple composite acid composition with skin lightening, skin rejuvenation and acne-removing effects, a product and application thereof, which comprises almond acid, salicylic acid and succinic acid, and the mass ratio of the almond acid, the salicylic acid and the succinic acid is 3-6:1-2:1-2. The application also provides a product containing the above composition and application thereof. The composition provided by the application is synergistically used, has a synergistic effect in terms of exfoliation, especially in terms of improving the activity of kallikrein 5 (KLK5), has not only the effects of biological skin rejuvenation and exfoliation, but also can efficiently down-regulate the expression of I-type 5alpha-reductase gene, thereby inhibiting the synthesis of sebum and playing an oil control role. In addition, the composition provided by the application has the effects of lightening, bacteriostasis and anti-inflammation, has low sensitization, can be used for acne removal, has rapid effect and is not repeated.

The present invention relates to a composition for preventing, improving, or treating inflammatory disease containing isookanin or a salt thereof as an active ingredient. The composition containing the isookanin or salt thereof as an active ingredient according to the present invention has no skin irritation and cytotoxicity, and thus has excellent safety for the human body. In addition, it has excellent effects on the inhibition of JAK1 activity, kallikrein-5 activity, TLR-2 activation, COX-2 expression and activity, prostaglandin PGE2 production, and PGE2-induced angiogenesis, and thus is very effective in preventing, alleviating and treating inflammatory disease. Accordingly, the composition containing the isookanin or salt thereof as an active ingredient according to the present invention may be useful as an active ingredient in a cosmetic composition, a pharmaceutical composition, a composition for skin application and a quasi-drug composition for preventing, alleviating or treating inflammatory disease.